Lumexa Imaging Holdings LMRI

NASDAQ LMRI

$11.74 +0.08 (+0.69%)

At close: Oct 26, 2026 · 4:00 PM EDT

Lumexa Imaging Holdings (LMRI) stock price is $11.74, up 0.69% on the day, as of Oct 26, 2026. It is classified in the Healthcare Services industry (Healthcare sector).

Key Stats

Add ratio to table…

About

Lumexa Imaging Holdings, Inc. is a national provider of outpatient diagnostic imaging services. The company operates a network of freestanding imaging centers that offer a full range of advanced and routine imaging modalities. As of September 30 2025 the company and its affiliates operated 184 centers across 13 states. The centers are located in attractive metropolitan statistical areas and provide services such as MRI CT PET X ray ultrasound and mammography. Lumexa Imaging focuses on delivering high quality care in convenient retail settings with extended hours to improve patient access. The company was established in 2018 under the name US Radiology Specialists by Charlotte Radiology and WCAS an investment firm with over 45 years of experience building successful companies in the healthcare and technology sectors. From 20 centers in 2018 the company expanded to 184 centers by September 30 2025 through 20 acquisitions and the opening of 41 de novo centers. Effective July 8 2025 US Radiology Specialists Holdings LLC changed its name to Lumexa Imaging Equity Holdco LLC. The company’s strategy emphasizes scaling its platform while maintaining high clinical standards and investing in third party technology and artificial intelligence solutions.

The company generates revenue primarily from fees charged for imaging procedures performed at its centers. Revenue is derived from commercial payors government programs such as Medicare and Medicaid and self pay patients. For the nine months ended September 30 2025 commercial payors contributed 58 percent of consolidated revenue while government payors contributed 28 percent and the remaining 14 percent came from self pay liens and other payors. Advanced imaging services including MRI CT and PET accounted for 52 percent of consolidated revenue and 63 percent of system wide revenue during the same period. Routine services such as X ray ultrasound and mammography provided the balance of revenue. The company also earns management fees from its health system joint venture partnerships. Revenue growth is driven by higher volumes of advanced imaging procedures and by expanding the center network through acquisitions and de novo openings. During the nine months ended September 30 2025 total consolidated revenue increased 7.8 percent to $755.3 million from $700.8 million in the prior year period. Adjusted EBITDA for the nine months ended September 30 2025 was $166.4 million representing an Adjusted EBITDA margin of 22.0 percent.

Lumexa Imaging holds the position of the second largest outpatient imaging provider in the United States by number of centers. The company competes with national regional and local operators including hospital outpatient departments independent diagnostic testing facilities and physician office based imaging providers. According to a 2025 analysis by Fortune Business Insights the total U. S. market for diagnostic imaging services was approximately $140 billion as of December 31 2024 and the market has grown at a 4.2 percent compound annual growth rate from 2019 to 2024. Freestanding imaging centers have grown faster than the overall market at a 6.9 percent compound annual growth rate over the same period. Lumexa Imaging benefits from the shift of volume from hospital based settings to independent diagnostic testing facilities driven by patient and payor preference for lower cost and more convenient care. The company’s competitive advantages stem from its scale its focus on advanced imaging modalities and its presence in high growth metropolitan statistical areas. Lumexa Imaging maintains a diversified referral network of over 100000 referring physicians representing more than 29000 physician practices. The company invests in third party technology such as RIS PACS RCM and artificial intelligence tools to improve efficiency report turnaround times and clinical quality. Lumexa Imaging also emphasizes low cost care offering services that are approximately 60 percent less expensive than comparable hospital outpatient department services based on a UnitedHealth Group analysis of 2019 claims.

The company serves a broad base of patients who receive imaging orders from referring physicians. Its customers include individual patients commercial health plans government agencies such as Medicare and Medicaid and health system joint venture partners. Specific customer names are not disclosed in the filing but the company reports relationships with major health systems including Baylor Scott & White Health Intermountain Health Integris Health Atrium Health Virtua Health Tenet Health Tucson Medical Center and UPMC. The referring physician network consists of more than 29000 physician practices representing over 100000 individual physicians. Patient satisfaction metrics show a patient Net Promoter Score of 91 and an overall patient satisfaction rate of 97 percent as of September 30 2025. Referring physician satisfaction indicates that 88 percent of participating physicians rated the company’s services as satisfied or higher as of December 31 2024. The company’s health system joint venture partnerships provide additional revenue streams and allow Lumexa Imaging to expand its footprint through shared capital investment and operational expertise. These joint ventures also help health systems reduce hospital backlogs and improve patient access to diagnostic imaging services.

Investment Thesis

▲ Bull case

The market appears to underestimate the margin expansion potential driven by the rapid adoption of FastScan MRI workflow software across the fleet. Management stated that FastScan installations are on track to reach approximately 67% of the MRI fleet by year end, up from 51% at the start of the year, and that centers equipped with FastScan are delivering productivity gains aligned with internal benchmarks. This technology reduces scan times, increases daily patient throughput, and allows the same fixed asset base to generate higher revenue without proportional increases in labor or overhead costs. As the penetration rate climbs, the incremental contribution to revenue per scan and overall EBITDA margin is likely to accelerate beyond the modest guidance range, especially when combined with the ongoing shift toward higher‑reimbursement advanced modalities. The company’s internal benchmarking suggests that each percentage point increase in FastScan adoption translates to a measurable uplift in scan volume per machine, which could compound the already strong 7% year over year growth in advanced modality volumes. Consequently, the market may be missing a hidden catalyst that could push adjusted EBITDA toward the upper end of the full‑year range or even exceed it if adoption outpaces current expectations.
Another underappreciated factor is the scalability and cash‑generating power of the joint venture model, which is already contributing a stable $15 million of equity in earnings from unconsolidated affiliates and is positioned to expand further with new health system partners. The CFO emphasized that JV structures are simple capital‑efficient vehicles that generate significant cash flows for both Lumexa and its partners, with cash distributions flowing directly into free cash flow as distributions from unconsolidated affiliates. The company highlighted a robust pipeline of potential JV partners and noted that the UPMC joint venture, initiated after an acquisition in Pennsylvania, is already providing a platform for accelerated de novo development. Because JV debt remains off the balance sheet at $82 million, the leveraged growth potential is not fully reflected in traditional leverage metrics, allowing the company to expand its footprint without increasing consolidated debt levels. As these joint ventures mature and contribute higher volumes of advanced imaging, the pro rata share of EBITDA and cash distributions is likely to grow, providing a steady, high‑quality income stream that is less sensitive to short‑term volume fluctuations than wholly owned centers.
The market may also be overlooking the cumulative impact of the disciplined de novo rollout plan, which targets eight to ten new centers per year and is already showing strong early performance. Two de novos were opened in the quarter in South Carolina and Florida, and the CFO noted that the 15 de novos opened since late 2024 are all ramping at or above internal expectations, gaining momentum quarter by quarter. Each new center adds a base of high‑margin advanced modality scans, and the company’s same‑center growth trajectory is supported by the ramp of these assets. The CFO indicated that the gradual sequential ramp in adjusted EBITDA throughout the year will be bolstered by the contribution of these de novos, with the majority of full‑year EBITDA expected in the second half as these sites reach steady state. Because the company finances growth through a mix of capital expenditures and lease arrangements, the cash outlay per de novo remains controlled, allowing the expansion to accrete to free cash flow over time. Investors focusing solely on the flat quarterly adjusted EBITDA may miss the latent earnings power that will emerge as the de novo base matures and the advanced modality mix continues to improve.
An additional source of upside lies in the expansion of AI‑driven strategic service lines, particularly the breast arterial calcification solution, which is generating strong patient uptake and represents a cash‑add‑on revenue stream with high incremental margin. Management highlighted continued rollout of the AI solution into new markets and noted strong continued patient uptake, indicating that the service is gaining traction beyond initial pilot sites. The AI offering leverages existing imaging equipment to create a new reimbursable or cash‑pay service that does not require significant additional capital investment, thereby enhancing the revenue per scan without proportionally increasing costs. As the company explores similar cash‑pay add‑ons for modalities such as CT and ultrasound, the potential to monetize AI across a broader portion of the fleet becomes increasingly plausible. The market’s current valuation appears to place limited weight on these emerging service lines, yet if adoption accelerates, they could contribute a meaningful lift to both revenue and adjusted EBITDA margin, especially when combined with the favorable payer mix shift toward outpatient settings that values lower‑cost, high‑quality imaging.
The company’s improved interest expense profile following the IPO‑driven debt paydown is another factor that the market may be underestimating, as it directly boosts cash flow and net income potential. The CFO reported that interest expense was $16 million in the quarter, down $14 million year over year, reflecting the use of IPO proceeds to pay down debt and freeing up more than $50 million in cash annually for reinvestment. This reduction in financing costs improves the conversion of operating cash flow to free cash flow, which was negative $2 million in the quarter but showed a $13 million year‑over‑year improvement. With a lower interest burden, the company can allocate more of its operating cash toward growth initiatives such as de novos, equipment upgrades, and strategic acquisitions without compromising liquidity. The market’s focus on the headline flat adjusted EBITDA may obscure the positive downstream effect of lower financing costs on earnings per share and cash generation, especially as the company scales its EBITDA base in the second half of the year.

The market appears to underestimate the margin expansion potential driven by the rapid adoption of FastScan MRI workflow software across the fleet. Management stated that FastScan installations are on track to reach approximately 67% of the MRI fleet by year end, up from 51% at the start of the year, and that centers equipped with FastScan are delivering productivity gains aligned with internal benchmarks. This technology reduces scan times, increases daily patient throughput, and allows the same fixed asset base to generate higher revenue without proportional increases in labor or overhead costs. As the penetration rate climbs, the incremental contribution to revenue per scan and overall EBITDA margin is likely to accelerate beyond the modest guidance range, especially when combined with the ongoing shift toward higher‑reimbursement advanced modalities. The company’s internal benchmarking suggests that each percentage point increase in FastScan adoption translates to a measurable uplift in scan volume per machine, which could compound the already strong 7% year over year growth in advanced modality volumes. Consequently, the market may be missing a hidden catalyst that could push adjusted EBITDA toward the upper end of the full‑year range or even exceed it if adoption outpaces current expectations.
Another underappreciated factor is the scalability and cash‑generating power of the joint venture model, which is already contributing a stable $15 million of equity in earnings from unconsolidated affiliates and is positioned to expand further with new health system partners. The CFO emphasized that JV structures are simple capital‑efficient vehicles that generate significant cash flows for both Lumexa and its partners, with cash distributions flowing directly into free cash flow as distributions from unconsolidated affiliates. The company highlighted a robust pipeline of potential JV partners and noted that the UPMC joint venture, initiated after an acquisition in Pennsylvania, is already providing a platform for accelerated de novo development. Because JV debt remains off the balance sheet at $82 million, the leveraged growth potential is not fully reflected in traditional leverage metrics, allowing the company to expand its footprint without increasing consolidated debt levels. As these joint ventures mature and contribute higher volumes of advanced imaging, the pro rata share of EBITDA and cash distributions is likely to grow, providing a steady, high‑quality income stream that is less sensitive to short‑term volume fluctuations than wholly owned centers.
The market may also be overlooking the cumulative impact of the disciplined de novo rollout plan, which targets eight to ten new centers per year and is already showing strong early performance. Two de novos were opened in the quarter in South Carolina and Florida, and the CFO noted that the 15 de novos opened since late 2024 are all ramping at or above internal expectations, gaining momentum quarter by quarter. Each new center adds a base of high‑margin advanced modality scans, and the company’s same‑center growth trajectory is supported by the ramp of these assets. The CFO indicated that the gradual sequential ramp in adjusted EBITDA throughout the year will be bolstered by the contribution of these de novos, with the majority of full‑year EBITDA expected in the second half as these sites reach steady state. Because the company finances growth through a mix of capital expenditures and lease arrangements, the cash outlay per de novo remains controlled, allowing the expansion to accrete to free cash flow over time. Investors focusing solely on the flat quarterly adjusted EBITDA may miss the latent earnings power that will emerge as the de novo base matures and the advanced modality mix continues to improve.
An additional source of upside lies in the expansion of AI‑driven strategic service lines, particularly the breast arterial calcification solution, which is generating strong patient uptake and represents a cash‑add‑on revenue stream with high incremental margin. Management highlighted continued rollout of the AI solution into new markets and noted strong continued patient uptake, indicating that the service is gaining traction beyond initial pilot sites. The AI offering leverages existing imaging equipment to create a new reimbursable or cash‑pay service that does not require significant additional capital investment, thereby enhancing the revenue per scan without proportionally increasing costs. As the company explores similar cash‑pay add‑ons for modalities such as CT and ultrasound, the potential to monetize AI across a broader portion of the fleet becomes increasingly plausible. The market’s current valuation appears to place limited weight on these emerging service lines, yet if adoption accelerates, they could contribute a meaningful lift to both revenue and adjusted EBITDA margin, especially when combined with the favorable payer mix shift toward outpatient settings that values lower‑cost, high‑quality imaging.
The company’s improved interest expense profile following the IPO‑driven debt paydown is another factor that the market may be underestimating, as it directly boosts cash flow and net income potential. The CFO reported that interest expense was $16 million in the quarter, down $14 million year over year, reflecting the use of IPO proceeds to pay down debt and freeing up more than $50 million in cash annually for reinvestment. This reduction in financing costs improves the conversion of operating cash flow to free cash flow, which was negative $2 million in the quarter but showed a $13 million year‑over‑year improvement. With a lower interest burden, the company can allocate more of its operating cash toward growth initiatives such as de novos, equipment upgrades, and strategic acquisitions without compromising liquidity. The market’s focus on the headline flat adjusted EBITDA may obscure the positive downstream effect of lower financing costs on earnings per share and cash generation, especially as the company scales its EBITDA base in the second half of the year.

▼ Bear case

The market may be ignoring the ongoing pressure on routine imaging volumes, which remained essentially flat quarter over quarter and could act as a drag on overall revenue growth despite strength in advanced modalities. Management acknowledged that mammography was taking longer to rebound after the storms and that routine scans were essentially flat, offsetting the gains from PET and MRI growth. While advanced modalities generate higher reimbursement, the fixed cost base of the business—including staffing, facility rent, and equipment payments—does not flex proportionally with short‑term volume changes, meaning that stagnation in the lower‑margin routine segment can compress overall margins. The CFO noted that the $4 million EBITDA impact from seasonality and weather was partly due to fixed cost absorption during lower volumes, and any prolonged weakness in routine scans would continue to pressure the contribution margin of the consolidated portfolio. Because the company’s guidance assumes a gradual ramp in volumes throughout the year, a slower‑than‑expected recovery in routine imaging could result in the full‑year revenue and EBITDA falling short of the midpoint of the guidance range.
Another risk that appears underappreciated is the potential for a more persistent shift in payer mix toward government programs, which typically offer lower reimbursement rates than commercial payers. Although management characterized the Q1 decline in commercial payer share as a normal seasonal pattern, the CFO admitted that there was “a bit more seasonality” in payer mix compared to the prior year, hinting at a possible structural change. If the trend toward a higher proportion of Medicare and Medicaid patients persists beyond the typical quarterly fluctuation, the average revenue per scan could face sustained downward pressure, eroding the benefit of the advanced modality mix shift. The company’s reliance on commercial payer rates for higher‑margin services means that any erosion in that mix would directly affect the adjusted EBITDA margin, which already declined from 20.8% to 20.3% year over year. The market’s current models may not be pricing in a scenario where the government payer share climbs and remains elevated for multiple quarters, thereby compressing profitability.
The sharp increase in stock‑based compensation expense, which doubled from $6 million to $12 million in the quarter due to the legacy equity plan reset tied to the IPO, represents a growing non‑cash drag on GAAP earnings that the market may be overlooking when focusing solely on adjusted metrics. The CFO indicated that full‑year stock‑based compensation is expected to be around $50 million, with an ongoing annual run‑rate of $20 million to $28 million starting in 2027. This substantial expense will continue to depress GAAP net income and EPS, potentially creating a divergence between adjusted performance and GAAP results that could concern investors who prioritize bottom‑line profitability. While the company expects the impact to diminish after the historic awards are fully amortized by 2026, the interim period will see elevated compensation costs that could weigh on investor sentiment, especially if the market begins to scrutinize the quality of earnings more closely.
The cybersecurity incident involving a vendor breach, although characterized by management as non‑material, introduces an unquantifiable operational and reputational risk that may be underappreciated. The CEO disclosed that a vendor experienced a breach that involved Lumexa data, but stated that they do not believe it has a material impact on business or financial results, offering little detail about the scope of the data exposed or the remedial actions taken. In an era where data breaches can trigger regulatory scrutiny, customer notification costs, and potential litigation, the lack of transparency leaves open the possibility of future financial repercussions that are not captured in current guidance. Moreover, the incident could erode trust with health system partners who are particularly vigilant about data security, potentially affecting future joint venture negotiations or renewal discussions. The market’s willingness to accept the non‑material assessment at face value may overlook the latent contingent liabilities that could emerge if further investigations reveal broader exposure.
Another area of concern is the off‑balance‑sheet debt associated with the joint ventures, which totals $82 million and represents equipment lease financing that is not reflected in Lumexa’s consolidated leverage metrics. While the CFO explained that JV debt is not on the balance sheet and that cash flows from operating activities already reflect JV operations, the existence of this debt creates a potential vulnerability if the joint ventures experience cash flow stress or if lease terms become less favorable. In a scenario where reimbursement pressures or volume shortfalls affect the JV sites, the ability to service this off‑balance‑sheet obligation could be compromised, potentially leading to calls for additional capital contributions from Lumexa or renegotiation of lease arrangements. Because the market typically evaluates leverage using on‑balance‑sheet debt, the true financial risk profile may be understated, especially as the company continues to rely on JVs for geographic expansion and capital‑efficient growth.

The market may be ignoring the ongoing pressure on routine imaging volumes, which remained essentially flat quarter over quarter and could act as a drag on overall revenue growth despite strength in advanced modalities. Management acknowledged that mammography was taking longer to rebound after the storms and that routine scans were essentially flat, offsetting the gains from PET and MRI growth. While advanced modalities generate higher reimbursement, the fixed cost base of the business—including staffing, facility rent, and equipment payments—does not flex proportionally with short‑term volume changes, meaning that stagnation in the lower‑margin routine segment can compress overall margins. The CFO noted that the $4 million EBITDA impact from seasonality and weather was partly due to fixed cost absorption during lower volumes, and any prolonged weakness in routine scans would continue to pressure the contribution margin of the consolidated portfolio. Because the company’s guidance assumes a gradual ramp in volumes throughout the year, a slower‑than‑expected recovery in routine imaging could result in the full‑year revenue and EBITDA falling short of the midpoint of the guidance range.
Another risk that appears underappreciated is the potential for a more persistent shift in payer mix toward government programs, which typically offer lower reimbursement rates than commercial payers. Although management characterized the Q1 decline in commercial payer share as a normal seasonal pattern, the CFO admitted that there was “a bit more seasonality” in payer mix compared to the prior year, hinting at a possible structural change. If the trend toward a higher proportion of Medicare and Medicaid patients persists beyond the typical quarterly fluctuation, the average revenue per scan could face sustained downward pressure, eroding the benefit of the advanced modality mix shift. The company’s reliance on commercial payer rates for higher‑margin services means that any erosion in that mix would directly affect the adjusted EBITDA margin, which already declined from 20.8% to 20.3% year over year. The market’s current models may not be pricing in a scenario where the government payer share climbs and remains elevated for multiple quarters, thereby compressing profitability.
The sharp increase in stock‑based compensation expense, which doubled from $6 million to $12 million in the quarter due to the legacy equity plan reset tied to the IPO, represents a growing non‑cash drag on GAAP earnings that the market may be overlooking when focusing solely on adjusted metrics. The CFO indicated that full‑year stock‑based compensation is expected to be around $50 million, with an ongoing annual run‑rate of $20 million to $28 million starting in 2027. This substantial expense will continue to depress GAAP net income and EPS, potentially creating a divergence between adjusted performance and GAAP results that could concern investors who prioritize bottom‑line profitability. While the company expects the impact to diminish after the historic awards are fully amortized by 2026, the interim period will see elevated compensation costs that could weigh on investor sentiment, especially if the market begins to scrutinize the quality of earnings more closely.
The cybersecurity incident involving a vendor breach, although characterized by management as non‑material, introduces an unquantifiable operational and reputational risk that may be underappreciated. The CEO disclosed that a vendor experienced a breach that involved Lumexa data, but stated that they do not believe it has a material impact on business or financial results, offering little detail about the scope of the data exposed or the remedial actions taken. In an era where data breaches can trigger regulatory scrutiny, customer notification costs, and potential litigation, the lack of transparency leaves open the possibility of future financial repercussions that are not captured in current guidance. Moreover, the incident could erode trust with health system partners who are particularly vigilant about data security, potentially affecting future joint venture negotiations or renewal discussions. The market’s willingness to accept the non‑material assessment at face value may overlook the latent contingent liabilities that could emerge if further investigations reveal broader exposure.
Another area of concern is the off‑balance‑sheet debt associated with the joint ventures, which totals $82 million and represents equipment lease financing that is not reflected in Lumexa’s consolidated leverage metrics. While the CFO explained that JV debt is not on the balance sheet and that cash flows from operating activities already reflect JV operations, the existence of this debt creates a potential vulnerability if the joint ventures experience cash flow stress or if lease terms become less favorable. In a scenario where reimbursement pressures or volume shortfalls affect the JV sites, the ability to service this off‑balance‑sheet obligation could be compromised, potentially leading to calls for additional capital contributions from Lumexa or renegotiation of lease arrangements. Because the market typically evaluates leverage using on‑balance‑sheet debt, the true financial risk profile may be understated, especially as the company continues to rely on JVs for geographic expansion and capital‑efficient growth.

Peer group

Peer Comparison

Companies in the Healthcare Services

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	102.46 Bn	14.98	1.31	49.72 Bn
2	NTRA	Natera, Inc.	58.02 Bn	-301.55	21.43	0.08 Bn
3	LH	Labcorp Holdings Inc.	26.92 Bn	26.86	1.88	5.86 Bn
4	DGX	Quest Diagnostics Inc	26.69 Bn	23.64	2.25	5.55 Bn
5	GH	Guardant Health, Inc.	23.05 Bn	-50.84	19.48	-
6	THC	Tenet Healthcare Corp	22.43 Bn	10.01	1.03	13.25 Bn
7	FMS	Fresenius Medical Care AG	13.25 Bn	12.11	1.20	541.49 Bn
8	EHC	Encompass Health Corp	12.25 Bn	19.73	1.97	2.63 Bn

Lumexa Imaging Holdings LMRI

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password